"Azacitidine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.
| Descriptor ID |
D001374
|
| MeSH Number(s) |
D02.145.150 D03.383.742.680.245.217 D13.570.685.245.217 D13.570.800.286.300
|
| Concept/Terms |
Azacitidine- Azacitidine
- 5-Azacytidine
- 5 Azacytidine
- Azacytidine
|
Below are MeSH descriptors whose meaning is more general than "Azacitidine".
Below are MeSH descriptors whose meaning is more specific than "Azacitidine".
This graph shows the total number of publications written about "Azacitidine" by people in this website by year, and whether "Azacitidine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 1 | 0 | 1 |
| 1994 | 1 | 0 | 1 |
| 1997 | 3 | 0 | 3 |
| 1998 | 1 | 0 | 1 |
| 1999 | 1 | 0 | 1 |
| 2002 | 5 | 0 | 5 |
| 2003 | 2 | 0 | 2 |
| 2004 | 1 | 0 | 1 |
| 2005 | 0 | 4 | 4 |
| 2006 | 4 | 3 | 7 |
| 2007 | 3 | 0 | 3 |
| 2008 | 1 | 0 | 1 |
| 2009 | 2 | 1 | 3 |
| 2010 | 1 | 1 | 2 |
| 2011 | 1 | 1 | 2 |
| 2013 | 3 | 2 | 5 |
| 2014 | 3 | 5 | 8 |
| 2015 | 3 | 1 | 4 |
| 2016 | 3 | 1 | 4 |
| 2017 | 5 | 1 | 6 |
| 2018 | 1 | 4 | 5 |
| 2019 | 2 | 2 | 4 |
| 2020 | 1 | 2 | 3 |
| 2021 | 1 | 1 | 2 |
| 2022 | 0 | 2 | 2 |
| 2023 | 3 | 4 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Azacitidine" by people in Profiles.
-
Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results. J Clin Oncol. 2023 11 01; 41(31):4893-4904.
-
From cell surface to nucleus: CCRL2 regulates response to hypomethylating agents in myelodysplastic syndromes. Haematologica. 2023 Jul 01; 108(7):1729-1730.
-
Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates. Blood Adv. 2023 06 13; 7(11):2360-2363.
-
Cellular Composition and 5hmC Signature Predict the Treatment Response of AML Patients to Azacitidine Combined with Chemotherapy. Adv Sci (Weinh). 2023 08; 10(23):e2300445.
-
Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL. Blood. 2023 05 04; 141(18):2194-2205.
-
Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study. Lancet Haematol. 2023 Apr; 10(4):e272-e283.
-
Novel treatment strategy of targeting epigenetic dysregulation in pancreatic neuroendocrine tumors. Surgery. 2023 04; 173(4):1045-1051.
-
A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes. Am J Hematol. 2023 02; 98(2):272-281.
-
Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia. Clin Cancer Res. 2022 07 01; 28(13):2744-2752.
-
Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine. J Clin Oncol. 2022 03 10; 40(8):855-865.